<DOC>
	<DOCNO>NCT00006091</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase II trial study effectiveness arsenic trioxide treat patient chronic phase chronic myelogenous leukemia respond previous treatment .</brief_summary>
	<brief_title>Arsenic Trioxide Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded Previous Treatment</brief_title>
	<detailed_description>OBJECTIVES : I . Determine rate complete major cytogenetic response arsenic trioxide demonstrate decrease percentage Philadelphia chromosome positive ( breakpoint cluster region bcr positive ) cell bone marrow patient interferon alfa refractory intolerant chronic phase chronic myelogenous leukemia . II . Determine rate duration complete hematological response treatment patient . III . Determine duration complete major cytogenetic response treatment patient . IV . Determine pattern clinical adverse experience improvement symptomatic parameter treatment patient . V. Determine time accelerate disease blast crisis overall survival patient receive treatment . VI . Determine effect treatment cytokine , apoptosis , angiogenesis patient . OUTLINE : Patients receive arsenic trioxide intravenous ( IV ) 2 hour either daily 15 consecutive day 5 day , 2 day total 15 dos . Treatment repeat every 2-5 week previous course maximum 12 course absence disease progression unacceptable toxicity . Patients achieve complete remission follow every month 3 month , every 2 month 6 month , every 3-4 month 1 year , every 6 month thereafter . All patient follow every 3 month 1 year annually thereafter . PROJECTED ACCRUAL : A total 17-53 patient accrue study within 2.5 year .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis Philadelphia ( Ph ) chromosome positive ( breakpoint cluster region bcr positive ) chronic myelogenous leukemia chronic phase Ineligible refuse allogeneic bone marrow transplantation Interferon alfa refractory intolerant define follow : Refractory : Failure achieve complete hematologic response last least 1 month prior therapy interferon alfa base regimen least 3 month 65 % Ph positive chromosome bone marrow one year interferon alfa base therapy At least 30 % increase Ph positive chromosome bone marrow sample take least one month apart OR An increase least 65 % Ph positive chromosome bone marrow Intolerant : Grade 3 great nonhematologic toxicity Autoimmune phenomenon grade No accelerate phase blastic phase disease define follow : Greater 15 % blast basophils peripheral blood bone marrow Greater 30 % blast plus promyelocytes peripheral blood bone marrow Documented extramedullary blastic disease outside liver spleen Platelet count le 100,000/mm3 unrelated therapy Clonal evolution ( additional chromosomal abnormality Ph chromosome ) solitary feature consider accelerated disease No known brain metastases central nervous system ( CNS ) disease PATIENT CHARACTERISTICS : Age : 12 Performance status : Zubrod 02 Life expectancy : At least 2 year Hematopoietic : See Disease Characteristics Hepatic : Unless due direct disease infiltration liver : ALT AST great 2.5 time upper limit normal ( ULN ) Bilirubin great 1.5 time ULN ( unless due Gilbert 's disease ) No hepatic disease would preclude study Renal : Creatinine great 1.5 time ULN Creatinine clearance least 60 mL/min Cardiovascular : No history New York Heart Association grade III IV cardiac disease No cardiovascular disease would preclude study No unstable angina pectoris cardiac arrhythmia would shorten life expectancy Other : No history grand mal seizure infantile febrile seizures No active secondary malignancy uncontrolled concurrent medical problem would shorten life expectancy No neurologic , endocrine , major systemic disease would preclude study No active infection uncontrolled oral IV antibiotic No history hypersensitivity study drug drug similar chemical structure No mental condition would preclude study Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : See Disease Characteristics No concurrent bone marrow peripheral blood stem cell transplantation Chemotherapy : At least 14 day since prior chemotherapy ( 48 hour hydroxyurea 6 week busulfan ) recover ( unless evidence rapidly progressive disease ) No concurrent cytotoxic chemotherapy No prior arsenic trioxide Endocrine therapy : No concurrent steroid treatment neoplasm ( except new adrenal failure ) No concurrent hormone treatment neoplasm ( except nondisease related condition ) Radiotherapy : At least 14 day since prior radiotherapy No concurrent radiotherapy Surgery : Not specify Other : At least 14 day since prior investigational agent No concurrent investigational antileukemic agent</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelogenous leukemia , BCR-ABL1 positive</keyword>
</DOC>